Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A predictive pharmacokinetic–pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination

(2013) Nadia Terranova et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Inhibition of AKT2 Enhances Sensitivity to Gemcitabine via Regulating PUMA and NF-κB Signaling Pathway in Human Pancreatic Ductal Adenocarcinoma

(2012) Dong Chen et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells

(2012) Shingo Kagawa et al.   JOURNAL OF SURGICAL RESEARCH

Pharmacokinetic/pharmacodynamic modelling of intracellular gemcitabine triphosphate accumulation: translating in vitro to in vivo

(2011) M.A. Battaglia et al.   IET Systems Biology

Identification of known drugs that act as inhibitors of NF-κB signaling and their mechanism of action

(2010) Susanne C. Miller et al.   BIOCHEMICAL PHARMACOLOGY

A Review of Trabectedin (ET-743): A Unique Mechanism of Action

(2010) Maurizio D'Incalci et al.   MOLECULAR CANCER THERAPEUTICS

Phenotype and Genotype of Pancreatic Cancer Cell Lines

(2010) Emily L. Deer et al.   PANCREAS

Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents

(2009) Kosalaram Goteti et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Methods of utilizing baseline values for indirect response models

(2009) Sukyung Woo et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Modeling of tumor growth and anticancer effects of combination therapy

(2009) Gilbert Koch et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Development of Yondelis® (trabectedin, ET-743). A semisynthetic process solves the supply problem

(2009) Carmen Cuevas et al.   NATURAL PRODUCT REPORTS

Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors

(2008) Wells A. Messersmith et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A model-based approach to the in vitro evaluation of anticancer activity

(2008) Francesca Del Bene et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY